HCPCS Level II code J1561 denotes a 500 mg vial of non-lyophilized immune globulin (gamunex-c/gammaked) for injectable administration. This code matters nationally because immune globulin products are commonly used across multiple specialties for immune deficiency, autoimmune disorders, and select acute indications; they are high-cost biologic therapies with implications for coverage, site-of-care decisions, and prior authorization policies. Key payers considered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context for J1561, typical sites of service where the product is administered, and payer coverage patterns. The publication summarizes benchmark pricing and utilization metrics where available, highlights relevant policy and reimbursement considerations that affect access and site-of-care choices, and outlines coding nuances tied to product formulation and billing. For elements not provided in the input—such as associated taxonomies, ICD-10 diagnoses, and related codes—the text states that data are not available in the input and omits those details.